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New insights into the regulation of the blood clotting cascade
derived from the X-ray crystal structure of bovine meizothrombin
des F1 in complex with PPACK 
Philip D Martin1, Michael G Malkowski1, Jeffrey Box2, Charles T Esmon2 and
Brian FP Edwards1
Background: The conversion of prothrombin to thrombin by factor Xa is the
penultimate step in the blood clotting cascade. In vivo, where the conversion
occurs primarily on activated platelets in association with factor Va and Ca2+
ions, meizothrombin is the major intermediate of the two step reaction.
Meizothrombin rapidly loses the fragment 1 domain (F1) by autolysis to become
meizothrombin des F1 (mzTBN-F1). The physiological properties of mzTBN-F1
differ dramatically from those of thrombin due to the presence of prothrombin
fragment 2 (F2), which remains covalently attached to the activated thrombin
domain in mzTBN-F1.
Results: The crystal structure of mzTBN-F1 has been determined at 3.1 Å
resolution by molecular replacement, using only the thrombin domain, and
refined to R and Rfree values of 0.205 and 0.242, respectively. The protease
active site was inhibited with D-Phe-Pro-Arg-chloromethylketone (PPACK) to
reduce autolysis. The mobile linker chain connecting the so-called kringle and
thrombin domains and the first two N-acetylglucosamine residues attached to
the latter were seen in electron-density maps improved with the program
SQUASH. Previously these regions had only been modeled.
Conclusions: The F2 kringle domain in mzTBN-F1 is bound to the
electropositive heparin-binding site on thrombin in an orientation that is
systematically shifted and has significantly more interdomain contacts
compared to a noncovalent complex of free F2 and free thrombin. F2 in
mzTBN-F1 forms novel hydrogen bonds to the carbohydrate chain of
thrombin and perhaps stabilizes a unique, rigid conformation of the g -autolysis
loop through non-local effects. The F2 linker chain, which does not interfere
with the active site or fibrinogen-recognition site, is arranged so that the two
sites cleaved by factor Xa are separated by 36 Å. The two mzTBN-F1
molecules in the asymmetric unit share a tight ‘dimer’ contact in which the
active site of one molecule is partially blocked by the F2 kringle domain of its
partner. This interaction suggests a new model for prothrombin organization.
Introduction
Bovine prothrombin is a single chain polypeptide con-
taining 582 amino acid residues (579 residues in humans)
and three carbohydrate chains [1–3] at asparagine residues
76Asn, 100Asn, and 373Asn60G (residue numbering is
explained in Figure 1). The penultimate step in the
blood clotting cascade converts the prothrombin zymogen
into the active, multifunctional enzyme a -thrombin
[4,5], which not only converts soluble fibrinogen into a
fibrin clot but also regulates the coagulation cascade [6].
Under physiological conditions, prothrombin is con-
verted by proteolysis to thrombin by the prothrombinase
complex (factor Xa, factor Va and Ca2+) on a negatively
charged phospholipid surface [7].
The prothrombin sequence includes fragment 1 (F1;
residues 1–155), fragment 2 (F2; residues 156–271), the A
chain (residues 272–320) and the B chain (residues
321–579). The A chain and B chain, which are linked by a
disulfide bond, jointly comprise the prethrombin-2 domain
when they are one polypeptide chain, as in prothrombin, or
the thrombin domain when they are separated as in
meizothrombin des F1 (mzTBN-F1). Prothrombin is con-
verted to active thrombin by cleavages at 271Arg, between
F2 and the A chain, and at 320Arg15, between the A and B
chains. In vivo, prothrombinase cuts first at 320Arg15 [8,9],
generating meizothrombin [10–12], and then at 271Arg,
releasing thrombin and the F1–F2 activation fragment,
which can be cleaved by thrombin into separate F1 and F2
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domains. In the the early phases of coagulation, the concen-
tration of meizothrombin exceeds that of thrombin [13] but
because the activation of prothrombin is rapid, there is little
build up of activation intermediates relative to the final
concentrations of thrombin. As two bonds are cleaved
rapidly during complete activation, the location and relative
proximity of the the two scissile bonds is significant. 
Distant from the active site, thrombin has two anion-
binding exosites formed by multiple, clustered arginine and
lysine residues. Exosite 1 interacts with acidic residues on
macromolecular ligands, such as fibrinogen, thrombomod-
ulin, the thrombin platelet receptor and heparin cofactor II
[14]; exosite 1 is also referred to as the fibrinogen recogni-
tion site. Compared to exosite 1, much less attention has
been devoted to the possible regulatory functions of the key
basic residues in exosite 2 [15]. Chemical modification and
mutational analysis have indicated that 409Arg93, 413Lys97,
418Arg101, 443Arg126, 490Arg165, 494Lys169, 498Arg173,
500Arg175, 565Arg233, 567Lys235, 568Lys236, and 572Lys240
within exosite 2 are important for heparin binding and
acceleration of thrombin inhibition by antithrombin [16–18].
Meizothrombin exhibits characteristics of both prothrombin
and thrombin. Meizothrombin and prothrombin have
similar molecular dimensions and binding affinities to pro-
coagulant membranes. Only minor differences in protein
secondary structure are detected by circular dichroism,
although the thermal denaturation profile of meizothrom-
bin in the presence of phosphatidyl-serine containing
membranes is slightly different from prothrombin [19].
Relative to thrombin in solution, meizothrombin exhibits
2–7% clotting activity, 35% amidolytic activity against
D-phenylalanyl-L-pipecolyl-L-arginyl-p-nitroanilide (S2238),
and 100% esterase activity [20,21]. In solution, meizothrom-
bin is a poorer activator of factor V than thrombin but on
negatively charged phospholipid vesicles, meizothrombin
becomes a better activator [13]. Exosite 1 in meizothrombin
seems to interact with thrombomodulin resulting in acceler-
ated protein C activation. In the presence of negatively
charged phospholipid membranes, protein C activation by
meizothrombin is enhanced approximately sixfold [22].
As activated protein C in turn inactivates factor Va,
meizothrombin is an important regulator of factor Va and
thus the clotting cascade in the early stages of prothrombin
activation when the concentration of meizothrombin rela-
tive to thrombin is relatively high [11].
Free meizothrombin is an unstable intermediate [9] in
that autolysis at the 155Arg–156Ser bond rapidly removes
the F1 domain to generate mzTBN-F1, which slowly
converts to thrombin. The cleavage site between the F1
and F2 domains is conserved in all known prothrombin
sequences [23], which suggests a significant role for
mzTBN-F1 in vivo. In vitro, mzTBN-F1 can be stabi-
lized by covalent inhibition with D-Phe-Pro-Arg-chloro-
methylketone (PPACK), as in these studies. Although
mzTBN-F1 reacts with thrombin substrates and peptide
inhibitors such as PPACK, electron spin resonance
probes show differences between the active site of
mzTBN-F1 and a -thrombin [24]. Also, heparin accelerates
the inhibition of thrombin by antithrombin III, but does
not accelerate the inhibition of mzTBN-F1 [25].
Kringle domains are common in blood coagulation proteins
[26] and the crystal structures of several are known ([27]
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Figure 1
mzTBN-F1 compared with the complex of
human thrombin and human F2. The Ca trace
of mzTBN-F1 (thick lines) is compared in
stereo with that of human F2 complexed with
human thrombin (thin lines) [29]. The
polypeptide chain linking the kringle domain of
F2 to the A chain of thrombin is highlighted
(very thick lines). Key residues in mzTBN-F1
are labeled: the N terminus of F2 (164Ser), the
cleavage site between F2 and the A chain
(271Arg), the C terminus of the A chain
(320Arg15), and the N and C termini of the B
chain (321Ile16 and 529Ser247). The molecules
were superimposed using only the thrombin
Ca coordinates (rms difference = 0.46 Å).
Residues in bovine prothrombin are identified
with the human prothrombin numbering
sequence [1] given as a superscripted prefix.
The three additional residues in bovine
prothrombin, 3AGly, 264AAsp and 264BPro, are
numbered as insertions. For continuity with
previous studies, residues in the kringle and
thrombin domains are also identified by a suffix
that gives their position in the canonical kringle
sequence (subscript k) [29] or in the
chymotrypsin sequence (suffix not
subscripted) [40], respectively. A sequence
table is provided as supplementary material
which is available with the internet version of
this paper.
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and references therein). Kringle domains are triple disul-
fide-bonded structures that have a characteristic oblate
spheroid shape with very little secondary structure. The two
kringle domains of prothrombin can be separated by prote-
olysis into F1 and F2. The crystal structures of F1 alone [28]
and of a noncovalent complex of human thrombin (hTBN)
with either human F2 (hF2.hTBN) or bovine F2
(bF2.hTBN) have been reported [29]. However, the 30
residues that link 248Cys79k (the last well defined residue in
F2 [29]) to 277Phe10 (the first well-defined residue in the A
chain of bovine thombin [30]) have only been modeled [30].
We present here the covalent structure of bovine mzTBN-
F1 from residue 164Ser to 579Ser247. The structure includes
the linker chain joining the thrombin and kringle domains,
the first two N-acetylglucosamine carbohydrate residues,
and a PPACK molecule covalently bound in the active site.
There are two mzTBN-F1 molecules in the crystallo-
graphic asymmetric unit, designated I and II. This struc-
ture, which reveals the ‘native’ conformation of the F2 and
thrombin domains of mzTBN-F1 for the first time, shows
major differences in the conformations of two key loops,
compared to thrombin, and reveals a novel interaction
between F2 and the carbohydrate chain.
Results and discussion
The F2 kringle domain and its interactions with thrombin
F2 divides naturally into three sections: 14 residues at the
N terminus that link the F2 kringle domain to F1; the F2
kringle domain (170Cys1k to 248Cys79k); and 25 residues of
a linker chain between the F2 kringle domain and the A
chain of thrombin. The first eight residues at the N termi-
nus of F2 (156Ser to 163Gln) are disordered in both mol-
ecules of mzTBN-F1 while the next six do not interact
with thrombin. The F2 kringle domain in mzTBN-F1,
however, interacts strongly with the thrombin domain.
There are 191 contacts (4.0 Å cut-off) between the kringle
and thrombin domains in molecule I and 170 between
these two domains in molecule II. 
Although the F2 kringle domain has diverged from the F1
kringle domain structure that was originally used to fit the
electron density [31], the core of the two kringle domains
is conserved. The root mean square (rms) deviation
between the two domains is 1.94 Å overall (superimposing
72 of the 79 kringle domain Ca atoms using ALIGN [32])
but falls to 0.69 for 36 Ca atoms in the core (using the
program OVERLAP). The major differences occur in
loops formed by residues 182Leu13k to 201Ala32k and
219Cys50k to 226Glu57k, both of which interact with the
thrombin domain. These two loops are similar to the cor-
responding loops in human F2 kringle domain [29], which
has an overall rms overlap of 0.71 with the bovine F2
kringle domain (superimposing 69 of the 79 Ca atoms).
A striking difference emerges, however, when mzTBN-F1
and hF2.hTBN (or bF2.hTBN) are superimposed with just
their thrombin domains. The Ca positions of the F2 kringle
residues nearest the thrombin surface superimpose closely
in the two complexes but those farthest from the thrombin
surface have Ca shifts that exceed 2.1 Å (Figure 1). This
global difference in the orientation of the F2 and thrombin
domains between the covalent and noncovalent complexes
is also evident at the kringle–thrombin interface. Molecules
I and II of MzTBN-F1 have 63 and 42 more kringle–throm-
bin contacts (£ 4 Å), respectively, than does hF2.hTBN.
Acidic residues on the F2 kringle domain cover and neut-
ralize complementary basic residues at exosite 2 (Figures
1 and 2; Table 1), the putative heparin-binding site of
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Figure 2
The interface between the F2 kringle domain
and thrombin. Residues between the thrombin
(red) and F2 kringle (blue) domains that are
within 5 Å of one another are shown in stereo.
Hydrogen bonds are shown as dashed lines
(green). For clarity, residues are identified only
by their prothrombin sequence position.
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thrombin [33–35]. Altogether, the F2 kringle domain covers
929 Å2 of the thrombin surface. Major hydrophobic contacts
occur between 230Trp61k and 409Arg93, 237Pro68k and
366Leu60, and 240Phe71k and 409Arg93. These interactions
shield 409Arg93 completely from the solvent. The electro-
static interactions between the F2 kringle and thrombin
domains in each mzTBN-F1 molecule are similar to those
seen in the noncovalent complex of human F2 with human
a -thrombin (hF2.hTBN) [29], but differ in detail. In
particular, 205Asp36k, 235Asp66k, 236Gln67k, 241Glu72k and
576Arg244 in bovine mzTBN-F1 are substituted by histi-
dine, glycine, lysine, glycine and glutamine, respectively, in
the human sequence. The extra salt links in mzTBN-F1
between 205Asp36k and 576Arg244, and between 241Glu72k
and 413Lys97 possibly contribute to the more intimate asso-
ciation at the kringle–thrombin interface in mzTBN-F1. 
The F2 linker segment and its interactions with thrombin
The polypeptide chain leaves the F2 kringle domain at
residue 248Cys79k and crosses to the thrombin domain with
253Asp forming salt bridges with thrombin residues
490Arg165 and 494Lys169 (Figure 3; Table 1). At 256Leu,
which fits into a hydrophobic pocket formed by 450Leu130,
487Leu162 and 506Phe181, the chain makes a sharp turn
into an extended segment that follows the thrombin
surface formed by the C-terminal domain of thrombin
(562His230 to 571Gln239). Between residues 264AAsp and
280Phe the chain forms a large W -shaped loop that extends
out into solution. The loop is mobile and the 2Fo–Fc elec-
tron density is broken for the four residues between 270Gly
and 273Ser (Figure 3). In a positional omit map, there are
intermittent breaks in the electron density between 261Gly
and 275Arg1R (not shown). The crystals contain mostly
mzTBN-F1 molecules with intact linker chains (Figure 4;
lane e, upper band with the same molecular weight as in
lane D) but also a significant fraction with cleaved linker
chains (Figure 4; lane e, lower band with the same
molecular weight as in lane C). At 270Glu1S, the electron
density is again good and clearly shows a stacked ring inter-
action between 281Phe1L and 286Phe1F. The interaction
between 280Phe1M and 281Phe1L previously observed in
the thrombin–rhodniin complex [30] is absent in mzTBN-
F1 because 264Pro partially occupies the position assumed
by the 280Phe1M sidechain in the rhodniin complex. The
sidechain of 280Phe1M is disordered in mzTBN-F1; it is
stabilized only after cleavage at 271Arg.
Both 281Phe1L and 286Phe1F are adjacent to a deep
hydrophobic pocket formed by the sidechains of 422Leu105,
574Ile242, 570Ile238, 353Ile47, 359Leu53 and 357Trp51. After
284Lys1I, the polypeptide chain follows the same A chain
trace seen in previous structures [34] . Altogether, the
linker chain forms 142 contacts with the thrombin domain
(4 Å cut-off) and covers 975 Å2 of the solvent-accessible
surface of the thrombin domain. 
Because a significant fraction of the linker chains between
the F2 and thrombin domains are cleaved in the crystals
(Figure 4; lane E), the electron density for this segment is
weaker than for the other domains. However, the 2Fo–Fc
electron density is continuous except for the four residues
between 270Gly and 273Ser which loop out above the surface
of thrombin (Figure 3). Although this large surface loop
makes the linker chain extremely flexible, the linker is
structurally significant in that the full effect of binding to
membrane lipids is transmitted to the prethrombin-2/throm-
bin domain only when the linker chain is intact [36].
The crystal structure of mzTBN-F1 shows that the linker
chain does not interfere with either the active site or
1684 Structure 1997, Vol 5 No 12
Table 1
Major polar interactions between fragment 2 and thrombin in
mzTBN-F1.
Fragment 2 Thrombin Distance (Å)* Type
†
residue residue Mol I Mol II Mol I/Mol II
Kringle domain 2
204Lys35k O 576Arg244 NH1 2.6 – H/–
205Asp36k OD1 576Arg244 NH2 3.4 2.7 S/H
205Asp36k OD2 576Arg244 NH2 2.9 – H/–
206Gln37k O 572Lys240 NZ 3.0 – H/–
207Asp38k OD1 572Lys240 NZ 2.8 – H/–
223Asp54k OD1 409Arg93 NH2 2.6 2.5 H/H
225Asp56k OD1 409Arg93 NH1 2.7 2.7 H/H
225Asp56k OD1 418Arg101 NH1 4.0 3.5 S/S
227Glu58k OE1 500Arg175 NH2 3.5 3.5 S/S
235Asp66k OD1 NAG-2 O6 2.8 2.6 h/h
235Asp66k OD2 NAG-2 O6 3.3 h/–
236Gln67k OE1 NAG-1 N2 3.4 –/h
236Gln67k OE1 NAG-1 O3 3.1 –/h
236Gln67k NE2 NAG-2 O5 3.4 – H/–
236Gln67k NE2 NAG-2 O6 3.2 – H/–
237Pro68k O 412Trp96 NE1 2.9 3.0 H/H
238Gly69k N 408Pro92 O 2.7 2.7 H/H
238Gly69k N 410Tyr94 O – 3.8 –/H
239Asp70k OD2 413Lys97 NZ 3.9 3.8 H/S
241Glu72k OE1 413Lys97 NZ 3.1 3.4 H/H
242Tyr73k OH 409Arg93 NH1 – 2.8 –/H
242Tyr73k OH 411Asn95 ND2 – 3.1 –/H
242Tyr73k OH 417Asp100 OD2 3.9 – H/–
242Tyr73k OH 500Arg175 NH2 3.2 3.9 H/H
Linker
253Asp OD2 490Arg165 NH1 – 2.9 –/H
253Asp OD1 494Lys169 NZ 3.6 3.5 H/S
253Asp OD2 494Lys169 NZ 3.5 2.8 H/H
256Leu O 565Arg233 NH1 3.4 3.0 H/H
259Arg NH1 503Asp178 OD2 2.6 – H/–
259Arg O 565Arg233 NH2 2.6 3.4 H/H
260Leu O 565Arg233 NH2 – 3.6 –/H
263Asp OD1 568Lys236 NZ 3.6 3.3 H/H
264AAsp OD2 571Gln239 NE2 – 3.3 –/H
265Asp OD2 571Gln239 NE2 2.9 – H/–
270Gly O 272Thr1U N 2.9 2.6 H/H
*Interactions between atoms separated by more than 4 Å were excluded.
†H indicates a hydrogen bond identified by QUANTA (Molecular
Simulations), h indicates a possible hydrogen bond whose angles exceed
the default limits in QUANTA and S indicates a salt bridge.
exosite, in agreement with the modeled linker chain of van
de Locht et al. [30]. The crystal structure also shows,
however, that the two bonds cleaved by prothrombinase are
approximately 36 Å apart, as opposed to the value of 15 Å
stated for the model [30]. The model was developed from
the orthorhombic crystal structure of the thrombin–rhod-
niin complex (PDB entry code 1TBQ) which has reason-
able electron density for the first 12 N-terminal residues of
thrombin (272Thr1U to 283Glu1J); these residues were dis-
ordered in all other thrombin structures. As shown in Figure
5, the mzTBN-F1 structure matches the traces for the two
thrombin molecules in 1TBQ up to the point where the two
traces in 1TBQ diverge from each other due to different
crystal contacts. Although the two N-terminal 271Thr1U
residues in 1TBQ are 12 Å or more from 271Thr1U residue
in mzTBN-F1 (Figure 5), they are still approximately the
same distance (31 Å and 37 Å) from the 320Arg15 scissile
bond in prethrombin-2 [30] as is 271Thr1U in mzTBN-F1
(36 Å). One should note, however, that the mobile, protrud-
ing loop between 262Glu and 275Asp in mzTBN-F1 has
enough flexibility to reduce the 36 Å gap between the two
cleavage sites to 15–20 Å to facilitate channeling of the
meizothrombin intermediate [10]. The conformational
changes induced in factor Xa and prothrombin by mem-
branes containing phosphatidylserine [37] might contribute
to such a reduction.
Novel features of the thrombin domain
The thrombin domains of mzTBN-F1 molecules I and II
have rms overlaps for the C a atoms [38] of 0.42 Å or less
relative to bovine and human thrombin [39,40]. Two
chain segments with well defined electron density differ
significantly from free thrombin, relative to the esti-
mated 0.4 Å error in the structures [41]. Firstly, the g -
autolysis loop, encompassing residues 466Glu146 to
474Glu149E, has a novel structure that exhibits C a
differences as high as 6 Å compared to free thrombin
(Figure 6). This novel conformation is stabilized by a
type I b turn and a hydrogen bond (2.9 Å) between
471Ser149B and 474Glu149E, by a hydrogen bond (3.2 Å)
between 469Thr149 O g 1 and 474Glu149E O e 1, and by an
ionic hydrogen bond (3.4 Å) between 465Arg145 and
474Glu149E O e 2. There is also a hydrophobic interaction
between the sidechains of 468Trp148 and 472Val149C.
The loop, which is 12 Å from the active site, is a compact
structure and protrudes some 15 Å above the globular
surface of the thrombin domain. 
The g -autolysis loop is generally disordered in thrombin
[42–44] unless it is stabilized by crystal contacts [45]. The
only exception to this was observed in the crystal structure
of human thrombin complexed with a receptor peptide in
which the g -autolysis loop had no crystal-packing contacts
Research Article  Meizothrombin des F1 Martin et al.    1685
Figure 3
The linker chain. Electron density at the 0.8s
level is shown in stereo for the linker chain in
a 20–3.1 Å 2Fo–Fc map calculated with
XPLOR for molecule I (the map for molecule II
is similar). A related figure showing thrombin
residues within 5 Å of the linker chain is
available with the internet version of this
paper.
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but still has a reasonably well-defined conformation
(average B value of 50 Å2) for all but one of its residues
[46]. In this case, the stable conformation is attributed to a
conformational change induced by the bound peptide in
exosite 1 [47]. In the case of mzTBN-F1, the novel
g -autolysis loop which is quite rigid (average B value of
22 Å2), is stabilized by three intrachain hydrogen bonds,
an internal hydrophobic contact, and one hydrophobic
crystal contact (70 Å2). By comparison, the g -autolysis loop
in the hirudin–thrombin complex [45], which is strongly
stabilized by crystal-packing contacts (346 Å2), has a
higher average B value of 35 Å2.
Compared to other thrombin structures, the rigidity and
internal interactions of the g -autolysis loop in mzTBN-
F1 are extraordinary for a chance conformation stabilized
by a minor crystal contact. Alternatively, the g -autolysis
loop could represent a ‘zymogen’ conformation that is
present in prothrombin, retained in mzTBN-F1, lost in
thrombin, and not recovered in hF2.hTBN. We surmise
that this zymogen conformation is stabilized during pro-
thrombin folding primarily by F1 (e.g., see the prothrom-
bin model discussed below), and secondly by F2. When
F1 is removed, the zymogen conformation becomes
thermodynamically less stable in mzTBN-F1 than the
disordered state. However, an activation barrier, namely
breaking the internal interactions of the loop, is main-
tained by F2. When F2 is removed, the loop is further
destabilized and unfolds. When F2 is added back to
thrombin, as in hF2.hTBN, the loop remains disordered,
because that is the lower free energy state. Insulin,
which folds as proinsulin but cannot refold as insulin is
the classic example. The observation that free F2 binds
to thrombin differently from F2 in mzTBN-F1 might
also be a contributing factor (Figure 1). F2, which is
distant from the g -autolysis loop, presumably influences
the loop through non-local effects as has been observed
for structural changes in other systems [48]. When the
surface residues that anchor the g -autolysis loop are com-
pared in mzTBN-F1 and in bovine thrombin there are
differences in hydrogen bonding and shifts in C a posi-
tions in the range of 0.5–1.2 Å. The differences approach
the order of our estimated error at 3.1 Å resolution they
are suggestive but not conclusive.
Figure 5
The cleavage site between F2 and thrombin.
The Ca trace of mzTBN-F1 (thick lines) for
residues 262Glu–292Asp1A is shown in stereo
superimposed with the corresponding
residues (thin lines; N termini labeled T-1U (1)
and T-1U (2)) of the two thrombin molecules
in the orthorhombic crystal structure of
thrombin complexed with rhodniin (PDB entry
1TBQ) [30]. The dashed lines show the
distances between the N termini of human a -
thrombin (1TBQ) and the corresponding
residue, 272Thr1U, in mzTBN-F1. The rms
deviation between the thrombin domain of
mzTBN-F1 and both thrombin molecules in
1TBQ is 0.47 Å for 286 of the 308 Ca atoms.
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Figure 4
Analysis of the mzTBN-F1 crystals. Polyacrylamide electrophoresis gel
run under non-reducing conditions showing (a) molecular weight
standards (94, 67, 43, 30, 20 and 14.4 kDa), (b) prothrombin, 
(c) a -thrombin, (d) mzTBN-F1 before crystallization and (e) mzTBN-F1
after the crystals were washed with holding buffer.
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The novel conformation of the g -autolysis loop could
influence the activity of mzTBN-F1 towards substrates
such as fibrinogen. When a non-cleavable analog of residues
7–23 of the fibrinogen Aa chain [49] is modeled into the
active site of mzTBN-F1, there are no major steric con-
flicts and the P1 residue, which is arginine at position 16,
fits snugly into the enzyme’s specificity pocket. With the
Aa chain modeled into the active site in this manner, the
arginine at position 19 (P3 ¢ ) is located 6 Å away from the
g -autolysis loop. As the fibrinogen Aa chain loops out at
this point and reinserts itself several residues later into the
anion-binding exosite [50], it is possible that it could inter-
act with the g -autolysis loop.
The second region in the thrombin domain that differs
significantly from free thrombin is centered at the
Tyr-Pro-Pro-Trp (YPPW loop; residues 367Tyr60A to
370Trp60D) and the adjacent Lys97 segment containing
residues 412Trp96 and 413Lys97. These two chain segments
exhibit Ca differences of up to 2.5 Å and 1.8 Å, respec-
tively, relative to thrombin (Figure 7) and form part of the
S9 subsite of thrombin [39] (according to the convention
of Schechter and Berger for naming protease substrate
residues and the corresponding enzyme subsites that bind
them [51]). The Lys97 segment in molecule I interacts
with its own kringle domain (Table 1) and YPPW loop
(412Trp96 contacts 368Pro60B). Similar relationships exist
for the Lys97 segment and YPPW loop in molecule II
(Tables 1 and 2).
One of the reasons for the greater substrate specificity of
thrombin, as compared to trypsin, is the presence of the
YPPW loop inserted near the active site where it sterically
restricts access and forms one side of the unique S2 speci-
ficity site of thrombin [39,40]. The original impression that
the YPPW loop is a rigid part of the active site [34] is con-
tradicted by the drastic difference in Ca positions (2.5 Å
for 370Trp60D) between mzTBN-F1 and thrombin. The
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Figure 6
The g -autolysis loop. (a) The mzTBN-F1 g -
autolysis loop is shown in stereo superimposed
with the same loop in thrombin [39]. The loop
has moved over 6 Å between the two
structures. (b) In contrast to previous
structures, the g -autolysis loop has well-defined
electron density as shown in a 7–3.1 Å 2Fo–Fc
map contoured at the 1s level.
6.2 Å 6.2 Å
Glu146466 Glu146466
468 Trp148468 Trp148
Ser149B471 Ser149B471
Structure
(a)
(b)
shifted position of the YPPW loop in mzTBN-F1 relative
to thrombin illustrates dramatically the range of move-
ment available to the loop, but cannot be attributed
wholly to the presence of F2 in mzTBN-F1. The F2
domain contacts the 413Lys97 segment adjacent to the
YPPW loop (Table 1) but not the YPPW loop directly.
Moreover, the YPPW loop interacts with a neighboring
mzTBN-F1 molecule in the crystal (Table 2). 
Carbohydrate interactions with F2
The first two N-acetylglucosamine (NAG) residues
attached to 373Asn60G (Figure 8) stabilize the domain
interface by forming hydrogen bonds to residues 235Asp66k
and 236Gln67k in the kringle domain (Figure 2; Table 1). In
addition, the NAG-1 N-acetyl CH3 contacts the hydro-
phobic sidechains of 366Leu60 and 368Pro60B (not shown).
All these interactions, which are unique to this structure,
provide a hitherto undetected route for cross-talk between
the F2 and thrombin domains. These hydrogen bonds are
not seen in hF2.hTBN [29], perhaps because it is assem-
bled from separate F2 and thrombin molecules that bind in
a significantly different orientation from that seen in
mzTBN-F1 (Figure 1). Although 235Asp66k and 236Gln67k
are replaced by glycine and lysine, respectively, in
hF2.hTBN, 236Lys67k NZ is within hydrogen-bonding dis-
tance of O3 in NAG-1 and O6 in NAG-2 when hF2.hTBN
is superimposed onto mzTBN-F1.
Correlations between the structure and function of
mzTBN-F1
The structure of mzTBN-F1 suggests why it is not as active
as thombin towards fibrinogen and protein C. The inhibi-
tion of fibrinogen cleavage is consistent with a 1:1 stoichio-
metric complex of thrombin and F2, and has an apparent
Kd of 7.5 m M. When a non-cleavable analog of residues
7–23 of the fibrinogen Aa chain [49] is modeled into the
active site of mzTBN-F1, residue 7 in the analog is posi-
tioned 7 Å from the F2 domain. This close approach opens
the possibility that residues 1–6 in native fibrinogen, which
do not affect the proteolysis of fibrinogen by thrombin [52],
inhibit fibrinogen proteolysis by meizothrombin and
mzTBN-F1 through an interaction with F2. 
1688 Structure 1997, Vol 5 No 12
Table 2
‘Dimer’ interactions between mzTBN-F1 molecules I and II.
Fragment 2 Thrombin Distance (Å) Type of interaction
Mol I F2–TBN Mol II Mol II F2–TBN Mol I
244Asp75k OD2 367Tyr60A OH 3.2 2.7 Hydrogen bond
244Asp75k O 370Trp60D NE1 3.4 2.8 Hydrogen bond
249Glu OE1 553Arg221A NH1 2.9 Hydrogen bond
188Gly19k CA 412Trp96 CZ3 3.5 3.5 Hydrophobic?
Figure 7
The YPPW loop. mzTBN-F1 (thick lines) and
the thrombin enzyme–substrate analog
complex (thin lines) [49] are shown in stereo
at the YPPW and the 413Lys97 loops. Major
movements are seen because the loops move
in a linked, concerted fashion caused by the
hydrogen bonds formed to kringle domain
residues 237Pro68k and 241Glu72k.
Trp60D Trp60D
2.5 Å 2.5 Å
2.9 Å 2.9 Å
3.1 Å 3.1 Å
370 370
Tyr60A367 Tyr60A367
Trp96412 Trp96412
Pro68k237 Pro68k237
Glu72k241 Glu72k241
Lys97413 Lys97413
Structure
Thrombin functions as an anticoagulant through thrombo-
modulin-enhanced hydrolysis of protein C. Thrombomod-
ulin can exist with or without a covalently associated
chondroitin sulfate moiety. The chondroitin sulfate
moiety increases the affinity of thrombomodulin for
thrombin about tenfold. Mutation of 409Arg93, 413Arg97
and 418Arg101 within exosite 2 largely eliminates the
chondroitin sulfate contribution to the binding affinity.
Interaction of the chondroitin sulfate with thrombin is
masked by F2 addition to thrombin and in mzTBN-F1
[53]. In addition, F2 behaves as a competitive inhibitor of
the bovine thrombomodulin interaction with thrombin
[54]. Thus, thrombomodulin molecules containing chon-
droitin sulfate interact less strongly with meizothrombin
and mzTBN-F1 because F2 blocks exosite 2. These
observations together with the structure of mzTBN-F1
suggest that proteins and glycosaminoglycans can modu-
late the specificity of thrombin through strong interactions
with exosite 2.
The noncrystallographic dimer suggests a model for
prothrombin
The active site of the thrombin domain in mzTBN-F1
molecule I is partially blocked by the noncrystallographic
‘dimer’ packing contact with the kringle domain of mol-
ecule II and vice versa (Table 2). This contact buries
1762 Å2 of surface area on each mzTBN-F1 molecule. The
only noncrystallographic dimer contact between the two
kringle domains is a ring stacking interaction between
their 187His residues.
The extensive interaction between the thrombin active site
of each mzTBN-F1 in the noncrystallographic dimer and
the F2 kringle domain of the opposite mzTBN-F1, sug-
gests a possible conformation (Figure 9) for meizothrombin
and prothrombin that is alternative to, or perhaps comple-
mentary to, a previous, ‘extended’ model of prothrombin,
which places thrombin and F1 on opposite sides of F2
[55]. The extended conformation described previously
does not explain recent experimental observations of
direct interaction between the F1 and prethrombin-2
domains of prothrombin [36] and between 55Arg in F1 and
the active site of meizothrombin [22,56]. If one assumes,
however, that the F2 position in mzTBN-F1 molecule II
approximates to the binding site for the absent F1 kringle
domain in mzTBN-F1 molecule I (and vice versa) and
then superimposes F2 in molecule II with either calcium-
free F1 [57] or calcium-loaded F1 [28], one arrives at a
new, ‘bent’ conformation of meizothrombin that places
the 55Arg bond in F1 within 15 Å of the active site. In
calcium-free meizothrombin, this bond is cleaved autolyti-
cally by the active site on the same molecule [56]. The
extended conformation of prothrombin has a correspond-
ing distance between 55Arg and the thrombin active site of
over 50 Å [55].
The bent conformation of meizothrombin predicts a
maximum vertical height of 90 Å for calcium-loaded pro-
thrombin or meizothrombin bound to a membrane,
which agrees well with the experimental value of
90 ± 10 Å [19]. There are no steric conflicts with the
calcium-loaded g -carboxyglutamic acid (Gla) domain
(residues 1–33 of prothrombin). The modeled conforma-
tion contains three ionic bonds and has a buried surface
area of 485 Å2 between the F1 kringle domain and
thrombin. This conformation positions both the C termi-
nus of the F1 kringle domain (143Cys79k) and the N ter-
minus of the F2 kringle domain (170Cys1k) lying on the
surface of the model with a separation of 44 Å that can be
comfortably spanned by the 26 intervening residues.
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Figure 8
The polysaccharide chain. The two N-acetyl-
glucosamines (NAGs) attached to 373Asn60G
are shown in stereo in the electron-density
map. The electron density is from the final
2Fo–Fc map contoured at the 0.8s level.
NAG-2 NAG-2
NAG-1 NAG-1
Pro60B368Pro60B368
Leu60366 Leu60366Asn60G373 Asn60G373
Gln67k236 Gln67k236
Asp66k235 Asp66k235
Structure
Biological implications
Hemostasis requires that the interactive sites of the
proenzymes involved in the blood clotting cascade be
cryptic until activated. Prothrombin is one such proen-
zyme involved in this cascade. Under physiological con-
ditions, prothrombin is converted by proteolysis to
thrombin by the prothrombinase complex (factor Xa,
factor Va and calcium). Active thrombin is involved in
the formation of a fibrin clot and regulation of the coagu-
lation cascade. Meizothrombin des F1 (mzTBN-F1) is
an intermediate in the conversion of prothrombin to
thrombin and its structure is described here. The struc-
ture of mzTBN-F1 reveals some interesting features of
the protein that provide insights into the ways in which
the clotting cascade is regulated. 
Firstly, mzTBN-F1 and its precursor, meizothrombin,
are capable of downregulating thrombin production.
Their own activity is, in turn, regulated by several
factors including heparin which binds to both thrombin
and antithrombin III and thereby accelerates the inhibi-
tion of thrombin by the latter. The structure of mzTBN-
F1 reveals that this heparin-binding site is masked by a
fragment (F2) such that the proenzymes can circulate
freely, being available to downregulate thrombin produc-
tion without themselves being immediately inactivated at
the clotting site.
Secondly, the F2 fragment of mzTBN-F1 contains a
linker chain which connects the F2 and thrombin
domains. The mzTBN-F1 structure shows that the
linker chain is flexible so that it can be cleaved readily by
factor Xa and not restrict the movement of the fragment
1 (F1) and F2 domains relative to the rest of the protein
that occurs when prothrombin binds to the prothrombi-
nase complex [37]. This movement might include a ‘bent’
conformation of prothrombin.
This work has also shown that covalently linked domains
can differ in structure from the equivalent complex
reassembled from separated domains. The structure of
mzTBN-F1, with covalently attached F2, was compared
to that of a noncovalent, reassembled complex of free
thrombin and free F2. The relative orientations of some
of the domains differ in the covalent and reassembled
complexes. In addition, some of the domains in the cova-
lent complex are more intimately associated, as evidenced
by the presence of 40–60 additional interdomain contacts.
The observed conformation of a loop in mzTBN-F1, the
g -autolysis loop, was completely different from that seen
in the noncovalent complex or in free thrombin. This loop
forms the major structural difference between the throm-
bin domain of mzTBN-F1 and free thrombin and is
possibly linked to the 50% drop in clotting activity of
freshly generated thrombin after one to two days of
storage (L McCoy and D Walz, unpublished results).
Presumably the g -autolysis loop in thrombin, which is
near the fibrinogen-recognition site, has the mzTBN-F1
conformation initially, but then slowly unfolds into the
mobile, disordered loop of mature, ‘stabilized’ thrombin.
This conformational change could have a role to play in
the regulation of thrombin activity and specificity in vivo.
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Figure 9
Model of prothrombin. The model was
constructed from the structure of mzTBN-F1
molecule I and the structure of calcium-loaded
bovine F1 [28] superimposed with the F2
kringle domain of mzTBN-F1 molecule II (not
shown).
Gla domain Gla domain
Kringle 1 Kringle 1
Kringle 2 Kringle 2Thrombin
 domain
Thrombin
 domain
Autolysis
   loop
Autolysis
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Arg271 Arg
271
Structure
Materials and methods
Bovine prethrombin-1 was purified by minor modifications of the
method of Owen [8]. Prethrombin-1 (2.5 mg/ml) was incubated with
the prothrombin activator from Echis carinatus venom (0.07 A280
units/mg prothrombin), 0.1 M NaCl, 0.02 M Tris, pH 7.5 with a twofold
molar excess of PPACK for 30 min at 37°C. The meizothrombin was
then separated from traces of thrombin and the venom by chromatog-
raphy on a Mono Q column. The column was developed with five
column volumes of a linear gradient going from 0.1 to 0.6 M NaCl in
0.02 M Tris, pH 7.5, reapplied to a Mono Q column, and eluted with
0.6 M NaCl, 0.02 M Tris, pH 7.5.
Crystals of PPACK inhibited mzTBN-F1 were grown in hanging drops at
room temperature, from a 17 mg/ml protein solution containing 1% to
4% polyethylene glycol (PEG) 4000 in 0.25 M (NH4)2PO4, pH 8.0 with
a 10:1 molar excess of PPACK. The protein was equilibrated against
reservoirs containing 32%–34% (NH4)2SO4 and 0.25 M (NH4)2PO4,
pH 8. Intensity data were measured with a Siemens X-1000 area detec-
tor system (RU 200 generator set at 40 KV, 70 mA, 4 circle goniometer,
graphite monochromator, 0.3 mm collimator, 20 cm detector distance,
14° 2q angle). Each frame of data contained ~2 million counts over a
0.25° rotation. Each data set was collected with a redundancy of ~2 and
a completeness > 90% to the desired resolution — usually 2.9 Å, [58] —
and reduced to structure amplitudes with XENGEN [59]. For all the dif-
fraction data sets that were measured, Rsym values were in the range
11% to 15% for 1 s (I) reflections. The crystal constants are a = 186.2 Å,
b = 186.2 Å, c = 120.2 Å, a = b = g = 90°.
The structure was solved by a combination of molecular replacement
with X-PLOR [60–62], solvent leveling [63], and graphics with
TOM/FRODO [64,65]. A rotation search with thrombin [39] as the
model (7–4 Å 4s data) followed by Patterson correlation refinement
(eight steps/peak) of the resulting 331 rotation function peaks pro-
duced two unambiguous solutions with correlation values that were the
highest (0.053) and fourth highest (0.041) in the list. Both orientations
gave unambiguous solutions to the translation function in P41212 that
had correlation coefficients of 0.16 or higher, were at least 10.5s
above the mean, and were 3.8s or more above the next highest peak.
The R value was 0.38 for molecule II in its original position and 0.44 or
worse for other origins relative to molecule I.
The number of molecules in the asymmetric unit was determined exper-
imentally from the crystal density [66] using crystals that were cross-
linked with 2% glutaraldehyde [67] for 1 h at 22°C, washed with
distilled water, and stained with an aqueous solution of carbol fuschin
dye to enhance visibility. The density of the colored crystal was
1.11 g/cc, which implies a molecular mass of 1.24 · 105 kDa in the
asymmetric unit, assuming a partial specific volume of 0.718 [68]. The
calculated mass of the mzTBN-F1, PPACK, and attached carbohydrate
is 5.12 · 104 kDa, which gives a value of 2.4 for the number of mol-
ecules in the asymmetric unit of the crystal. The value is greater than
2.0 due to some experimental error and the presence of gluteraldehyde
[66] and dye. 
Two F1 kringle domains [28] were fit into a solvent leveled, Fo–Fc
electron-density map [63] that was calculated after 120 cycles of
positional refinement using just the two thrombin domains. A 2Fo–Fc
map calculated with the F2 kringle sequence showed excellent
density for features that were not included in the phase calculations,
namely the PPACK molecule, the new conformation of the g -autolysis
loop, and the first two sugar residues of the thrombin carbohydrate
chain [69]. These new features were fit to the density and the refine-
ment continued with coolstage, positional, and B-factor refinement
using noncrystallographic symmetry (NCS) restraints of 300 kcal and
sig B restraints of 1. However, the refinement stalled at an R value of
24% and Rfree of 32%. An additional 13 data sets collected locally
and seven collected at Brookhaven National Laboratory did not
improve the refinement nor did a refit of the entire structure, ten
residues at a time, with ‘positional’ omit maps.
Fortuitously, data from a crystal soaked in 1 mM triethyl lead acetate
refined smoothly to R and Rfree values of 0.21 and 0.31, respectively,
with no evidence for a bound heavy atom in the electron-density
maps. The Rmerge value (0.13) of the lead derivative data with other
native data sets was similar to that between the other native data
sets. The improved electron-density maps allowed us to fit the linker
chain using SQUASH [70] to include low-angle data (20–7 Å) in
the maps (Figure 3). Phases were calculated from the model with no
linker chain atoms and then refined by cycles of solvent leveling and
histogram matching to convergence. The resultant electron density
was averaged using NCS, as many linker residues fit as the density
permitted, and the process was repeated with better phases from the
previous model. SQUASH was particularly effective because the
crystals are 76% solvent. A torsion slow cool stage and 60 cycles of
positional refinement gave values for R and Rfree of 0.194 and 0.304,
respectively, using 22,699 2 s (F) reflections between 7.0 Å and
3.1 Å and NCS restraints.
The refinement was continued with no NCS restraints and with 1 s
data to make it overdetermined. The 31,648 structure factors greater
than 1s in the 7 to 3.1 Å shell gave R and Rfree values of 0.223 and
0.273, respectively. The addition of 123 water molecules at stereo-
chemically reasonable positions with electron density at the 2.5s level
in both Fo–Fc and 2Fo–Fc maps lowered the R and Rfree to 0.205 and
0.242 after positional and B-factor refinement. The geometry in the final
model was excellent with rms deviations for bonds, angles, dihedrals,
and planes of 0.013 Å, 1.96°, 26.06°, and 1.72°, respectively. The
mean error is estimated to be 0.4 Å [41]. When analyzed by
PROCHECK, 94% of the residues fell within the allowed regions of a
Ramachandran plot, 3.5% were in the generously allowed regions and
2.4% were in disallowed areas.
Accession numbers
Coordinates and structure factors of the two molecules of meizothrom-
bin des F1 in the asymmetric unit have been deposited with the Protein
Data Bank with accession codes 1a0h and r1a0hsf, respectively. 
Supplementary material
Supplementary material available with the internet version of this manu-
script contains a sequence table and a figure related to Figure 3.
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